FAES FARMA

Faes Farma reports Q1 2026 sales of €200.1m (+31%), driven by the acquisitions of SIFI and Edol; organic sales growth was 10%. EBITDA rose to €48.2m (+23%; adjusted +30%) and net profit to €30.8m. Ophthalmology contributed €28.5m (14% of sales), international pharmaceutical business grew 92% and Latin America 23%. The company confirms its full-year guidance: sales +17–19% (€734–746m) and EBITDA €151–155m, with the target remaining a leverage ratio below two times EBITDA. » More on de.investing.com

Faes Farma reports revenue of €627.0m for 2025 (+23%), but net income attributable to shareholders fell 28.5% to €79.6m; results were weighed down by one‑off costs for the plant relocation to Derio and integration expenses from the acquisitions of Laboratorio Edol and SIFI. Adjusted EBITDA rose 3.1% to €132.8m, while reported EBITDA fell 8.4% to €118.0m. The acquisitions and international expansion, especially in Latin America, contributed strongly to revenue, while personnel costs and inventory buildup squeezed margins. For 2026 management expects revenue growth of 17–19% and an EBITDA increase of 28–31%, with a target to keep leverage below 2x EBITDA. » More on de.investing.com

Faes Farma recorded a 12.3% increase in revenue to €307.4 million in the first half of 2025, while net profit declined by 10.5% to €52.2 million due to one-off expansion and acquisition costs. International business and the animal nutrition division were key drivers of growth, while investments in new facilities and acquisitions temporarily impacted profitability. The company expects continued solid revenue growth for the full year and believes it is well positioned for long-term growth thanks to its strategic initiatives. » More on de.investing.com